These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

562 related articles for article (PubMed ID: 27637804)

  • 21. Age-dependent effects of A53T alpha-synuclein on behavior and dopaminergic function.
    Oaks AW; Frankfurt M; Finkelstein DI; Sidhu A
    PLoS One; 2013; 8(4):e60378. PubMed ID: 23560093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Behavioral characterization of A53T mice reveals early and late stage deficits related to Parkinson's disease.
    Paumier KL; Sukoff Rizzo SJ; Berger Z; Chen Y; Gonzales C; Kaftan E; Li L; Lotarski S; Monaghan M; Shen W; Stolyar P; Vasilyev D; Zaleska M; D Hirst W; Dunlop J
    PLoS One; 2013; 8(8):e70274. PubMed ID: 23936403
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A53T-alpha-synuclein-overexpression in the mouse nigrostriatal pathway leads to early increase of 14-3-3 epsilon and late increase of GFAP.
    Kurz A; May C; Schmidt O; Müller T; Stephan C; Meyer HE; Gispert S; Auburger G; Marcus K
    J Neural Transm (Vienna); 2012 Mar; 119(3):297-312. PubMed ID: 21960009
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resveratrol alleviates motor and cognitive deficits and neuropathology in the A53T α-synuclein mouse model of Parkinson's disease.
    Zhang LF; Yu XL; Ji M; Liu SY; Wu XL; Wang YJ; Liu RT
    Food Funct; 2018 Dec; 9(12):6414-6426. PubMed ID: 30462117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neurodegeneration by α-synuclein-specific T cells in AAV-A53T-α-synuclein Parkinson's disease mice.
    Karikari AA; McFleder RL; Ribechini E; Blum R; Bruttel V; Knorr S; Gehmeyr M; Volkmann J; Brotchie JM; Ahsan F; Haack B; Monoranu CM; Keber U; Yeghiazaryan R; Pagenstecher A; Heckel T; Bischler T; Wischhusen J; Koprich JB; Lutz MB; Ip CW
    Brain Behav Immun; 2022 Mar; 101():194-210. PubMed ID: 35032575
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased dopaminergic neuron sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in transgenic mice expressing mutant A53T alpha-synuclein.
    Yu WH; Matsuoka Y; Sziráki I; Hashim A; Lafrancois J; Sershen H; Duff KE
    Neurochem Res; 2008 May; 33(5):902-11. PubMed ID: 17999181
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes.
    Kuo YM; Li Z; Jiao Y; Gaborit N; Pani AK; Orrison BM; Bruneau BG; Giasson BI; Smeyne RJ; Gershon MD; Nussbaum RL
    Hum Mol Genet; 2010 May; 19(9):1633-50. PubMed ID: 20106867
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid Induction of Dopaminergic Neuron Loss Accompanied by Lewy Body-Like Inclusions in A53T BAC-SNCA Transgenic Mice.
    Okuda S; Uemura N; Sawamura M; Taguchi T; Ikuno M; Uemura MT; Yamakado H; Takahashi R
    Neurotherapeutics; 2022 Jan; 19(1):289-304. PubMed ID: 34935120
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of Ginkgo Biloba Extract on A53T α-Synuclein Transgenic Mouse Models of Parkinson's Disease.
    Kuang S; Yang L; Rao Z; Zhong Z; Li J; Zhong H; Dai L; Tang X
    Can J Neurol Sci; 2018 Mar; 45(2):182-187. PubMed ID: 29506601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuronal expression of familial Parkinson's disease A53T α-synuclein causes early motor impairment, reduced anxiety and potential sleep disturbances in mice.
    Rothman SM; Griffioen KJ; Vranis N; Ladenheim B; Cong WN; Cadet JL; Haran J; Martin B; Mattson MP
    J Parkinsons Dis; 2013; 3(2):215-29. PubMed ID: 23938351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human myeloperoxidase (hMPO) is expressed in neurons in the substantia nigra in Parkinson's disease and in the hMPO-α-synuclein-A53T mouse model, correlating with increased nitration and aggregation of α-synuclein and exacerbation of motor impairment.
    Maki RA; Holzer M; Motamedchaboki K; Malle E; Masliah E; Marsche G; Reynolds WF
    Free Radic Biol Med; 2019 Sep; 141():115-140. PubMed ID: 31175983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brain infusion of α-synuclein oligomers induces motor and non-motor Parkinson's disease-like symptoms in mice.
    Fortuna JTS; Gralle M; Beckman D; Neves FS; Diniz LP; Frost PS; Barros-Aragão F; Santos LE; Gonçalves RA; Romão L; Zamberlan DC; Soares FAA; Braga C; Foguel D; Gomes FCA; De Felice FG; Ferreira ST; Clarke JR; Figueiredo CP
    Behav Brain Res; 2017 Aug; 333():150-160. PubMed ID: 28668282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A53T Mutant Alpha-Synuclein Induces Tau-Dependent Postsynaptic Impairment Independently of Neurodegenerative Changes.
    Teravskis PJ; Covelo A; Miller EC; Singh B; Martell-Martínez HA; Benneyworth MA; Gallardo C; Oxnard BR; Araque A; Lee MK; Liao D
    J Neurosci; 2018 Nov; 38(45):9754-9767. PubMed ID: 30249789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CXCL12 is involved in α-synuclein-triggered neuroinflammation of Parkinson's disease.
    Li Y; Niu M; Zhao A; Kang W; Chen Z; Luo N; Zhou L; Zhu X; Lu L; Liu J
    J Neuroinflammation; 2019 Dec; 16(1):263. PubMed ID: 31831012
    [TBL] [Abstract][Full Text] [Related]  

  • 35. G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged mice.
    Novello S; Arcuri L; Dovero S; Dutheil N; Shimshek DR; Bezard E; Morari M
    Neurobiol Dis; 2018 Dec; 120():21-33. PubMed ID: 30172844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MLKL deficiency alleviates neuroinflammation and motor deficits in the α-synuclein transgenic mouse model of Parkinson's disease.
    Geng L; Gao W; Saiyin H; Li Y; Zeng Y; Zhang Z; Li X; Liu Z; Gao Q; An P; Jiang N; Yu X; Chen X; Li S; Chen L; Lu B; Li A; Chen G; Shen Y; Zhang H; Tian M; Zhang Z; Li J
    Mol Neurodegener; 2023 Dec; 18(1):94. PubMed ID: 38041169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peripheral inflammation exacerbates α-synuclein toxicity and neuropathology in Parkinson's models.
    La Vitola P; Balducci C; Baroni M; Artioli L; Santamaria G; Castiglioni M; Cerovic M; Colombo L; Caldinelli L; Pollegioni L; Forloni G
    Neuropathol Appl Neurobiol; 2021 Feb; 47(1):43-60. PubMed ID: 32696999
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A53T human α-synuclein overexpression in transgenic mice induces pervasive mitochondria macroautophagy defects preceding dopamine neuron degeneration.
    Chen L; Xie Z; Turkson S; Zhuang X
    J Neurosci; 2015 Jan; 35(3):890-905. PubMed ID: 25609609
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tauopathic changes in the striatum of A53T α-synuclein mutant mouse model of Parkinson's disease.
    Wills J; Credle J; Haggerty T; Lee JH; Oaks AW; Sidhu A
    PLoS One; 2011 Mar; 6(3):e17953. PubMed ID: 21445308
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic exposure to manganese decreases striatal dopamine turnover in human alpha-synuclein transgenic mice.
    Peneder TM; Scholze P; Berger ML; Reither H; Heinze G; Bertl J; Bauer J; Richfield EK; Hornykiewicz O; Pifl C
    Neuroscience; 2011 Apr; 180():280-92. PubMed ID: 21333719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.